Friday, March 20, 2015 11:47:47 AM
March 19, 2015 5:36 PM EDT by Ben Mahaney, Editor in Exclusively Published
•
Maxim Group's healthcare analyst Jason Kolbert came out with a research note on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), after the company reported its fourth-quarter financial results and provided a corporate update.
Kolbert noted, "Aeterna announced 4Q results, spending $11M in the quarter and closing the year with $35M in cash, which we add to the $47.2M the company raised (less $5.7M to extinguish outstanding warrants) in 1Q15. With a current net of ~$70M in cash, the company is well positioned to acquire commercial-stage products that fit with its female health focus. We also note that management guided to a reduced burn rate as a result of their restructured R&D effort, prolonging their cash runway."
Furthermore, "AEZS began selling EstroGel, a topical gel for hormone replacement, in December 2014. We expect to see the first launch results in 1Q15. While we believe EstroGel can be a good product we do not see it making a meaningful revenue contribution, instead we believe it helps the company build its commercial focus, setting the stage for additional product acquisitions, which, when combined, can be meaningful, or in other words Estrogel creates strategic value for the company beyond its revenue contribution."
The analyst rates the stock a Buy with a $2.00 price target, which implies an upside of 261% from current levels.
According to TipRanks.com, which measures analysts' and bloggers' success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 11.8% and a 46.2% success rate. Kolbert has a -30.5% average return when recommending AEZS, and is ranked #260 out of 3535 analysts.
__________________________________________
http://www.smarteranalyst.com/2015/03/19/maxim-reiterates-buy-aeterna-zentaris-inc-usa-following-4q14-update/
Jasaon now knows it is a gel!
AEZS
Recent CSCI News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/23/2024 11:30:23 AM
- COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs • GlobeNewswire Inc. • 09/23/2024 11:30:00 AM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 09/06/2024 06:04:41 PM
- COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency • GlobeNewswire Inc. • 08/27/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 12:05:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 12:05:17 PM
- COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/13/2024 12:05:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM